HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 201–300 of 1,001
CETP Inhibition: Past Failures and Future Hopes
Kosmas, C. E., DeJesus, E., Rosario, D., & Vittorio, T. J. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s32667 · Cited by 87
Vascular targeting of nanoparticles for molecular imaging of diseased endothelium
Atukorale, P. U., Covarrubias, G., Bauer, L., & Karathanasis, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.006 · Cited by 84
The Role of Anethum graveolens L. (Dill) in the Management of Diabetes
Goodarzi, M. T., Khodadadi, I., Tavilani, H., & Abbasi Oshaghi, E. (2016) · Journal of Tropical Medicine · doi:10.1155/2016/1098916 · Cited by 68
Identification and Management of Cardiometabolic Risk after Spinal Cord Injury
Nash, M. S., Groah, S. L., Gater, D. R., Dyson-Hudson, T. A., Lieberman, J. A., Myers, J., Sabharwal, S., & Taylor, A. J. (2019) · The Journal of Spinal Cord Medicine · doi:10.1080/10790268.2018.1511401 · Cited by 78
High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
Tuteja, S., & Rader, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.79 · Cited by 84
Angeloni, E., Paneni, F., Landmesser, U., Benedetto, U., Melina, G., Lüscher, T. F., Volpe, M., Sinatra, R., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht163 · Cited by 79
Abdalrada, A. S., Abawajy, J., Al-Quraishi, T., & Islam, S. M. S. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00968-z · Cited by 78
Ihedioha, J. I., Noel-Uneke, O. A., & Ihedioha, T. E. (2011) · Comparative Clinical Pathology · doi:10.1007/s00580-011-1372-7 · Cited by 78
“…which play the physiological role of vehicle for the delivery of cholesterol to peripheral tissues; in contrast, HDLC mobilizes cholesterol from developing and existing atheromas and transports it to the liver for excretion in bile (Libby et al. 1998; NCEP 2002; Schoen 2004; Barter et al. 2007).”
InfluentialAmarenco, P., Goldstein, L. B., Messig, M., O'Neill, B. J., Callahan, A., Sillesen, H., Hennerici, M. G., Zivin, J. A., & Welch, K. M. A. (2009) · Stroke · doi:10.1161/strokeaha.108.546135 · Cited by 76
Exploring the impact of bariatric surgery on high density lipoprotein
Aminian, A., Zelisko, A., Kirwan, J. P., Brethauer, S. A., & Schauer, P. R. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.07.017 · Cited by 86
“org elevated levels of LDL [4,5].”
HDL-cholesterol in coronary artery disease risk: Function or structure?
Pérez-Méndez, O. A., González‐Pacheco, H., Martínez‐Sánchez, C., & Franco, M. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.12.001 · Cited by 87
“Therefore, it is indubitable that HDL-cholesterol is an independent CAD biomarker [1–4], but its pharmacological elevation does not result in important reductions of CAD risk, or does not reflect an improvement of HDL metabolism.”
BackgroundMethodInfluentialThe influence of age on the association between cholesterol and cognitive function
van Vliet, P., van de Water, W., de Craen, A. J. M., & Westendorp, R. G. J. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2008.05.004 · Cited by 86
Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis
Sun, J., Fan, Z., Kou, M., Wang, X., Yue, Z., & Zhang, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1622988 · Cited by 74
Randomized Trials Versus Common Sense and Clinical Observation
Fanaroff, A. C., Califf, R. M., Harrington, R. A., Granger, C. B., McMurray, J. J. V., Patel, M. R., Bhatt, D. L., Windecker, S., Hernandez, A. F., Gibson, C. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.069 · Cited by 80
“Similarly, epidemiological studies demonstrated an association between low levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular mortality (19), but in RCTs, multiple HDL-C–raising drugs did not reduce cardiovascular events (20–24).”
BackgroundActivation of lecithin: cholesterol acyltransferase by HDL ApoA-I central helices
Sorci‐Thomas, M. G., Bhat, S., & Thomas, M. J. (2009) · Clinical Lipidology · doi:10.2217/17584299.4.1.113 · Cited by 76
Endoplasmic reticulum stress impairs cholesterol efflux and synthesis in hepatic cells
Röhrl, C., Eigner, K., Winter, K. S., Korbelius, M., Obrowsky, S., Kratky, D., Kovacs, W. J., & Stangl, H. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m043299 · Cited by 81
Fuertes-Martín, R., Taverner, D., Vallvé, J.-C., Paredes, S., Masana, L., Correig, X., & Grau, N. A. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00411 · Cited by 81
Lehto, S. M., Niskanen, L., Tolmunen, T., Hintikka, J., Viinamäki, H., Heiskanen, T., Honkalampi, K., Kokkonen, M., & Koivumaa‐Honkanen, H. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02079.x · Cited by 72
Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
Zivkovic, S., Maric, G., Cvetinovic, N., Lepojevic-Stefanovic, D., & Bozic Cvijan, B. (2023) · Nutrients · doi:10.3390/nu15061517 · Cited by 71
Metelskaya, V. A., Shalnova, S. A., Деев, А. Д., Nv, P., Gomyranova, N. V., Litinskaya, O. A., Евстифеева, С. Е., Artamonova, G. V., Гатагонова, Т. М., Grinshtein, Y. I., et al. (2016) · Russian Journal of Preventive Medicine · doi:10.17116/profmed201619115-23 · Cited by 95
Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome
O’Neill, B. J. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000569 · Cited by 71
“com patients have significant ‘residual risk [22].”
Familial hypercholesterolemia: current treatment and advances in management
Huijgen, R., Vissers, M. N., Defesche, J. C., Lansberg, P. J., Kastelein, J. J., & Hutten, B. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.4.567 · Cited by 71
Self-citationDyslipidemia is associated with an increased risk of nephrolithiasis
Masterson, J. H., Woo, J. R., Chang, D. C., Chi, T., L’Esperance, J. O., Stoller, M. L., & Sur, R. L. (2014) · Urolithiasis · doi:10.1007/s00240-014-0719-3 · Cited by 71
Apolipoprotein C-III is an Amyloid-β-Binding Protein and an Early Marker for Alzheimer's Disease
Shih, Y.-H., Tsai, K.-J., Lee, C.-W., Shiesh, S.-C., Chen, W.-T., Pai, M.-C., & Kuo, Y.-M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140111 · Cited by 70
Silent information regulator, Sirtuin 1, and age‐related diseases
Zeng, L., Chen, R., Liang, F.-X., Tsuchiya, H., Murai, H., Nakahashi, T., Iwai, K., Takahashi, T., Kanda, T., & Morimoto, S. (2009) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2008.00504.x · Cited by 73
In vivo antihyperlipidemic and antioxidant activity of porphyran in hyperlipidemic mice
Wang, X., Li, W., Li, X., Liu, C., Qi, H., & Zhang, Z. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.06.040 · Cited by 72
Zhong, Z., Hou, J., Zhang, Q.-F., Zhong, W. H., Li, B., Li, C., Liu, Z., Yang, M. H., & Zhao, P. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-0979-6 · Cited by 79
High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease
Akinkuolie, A. O., Paynter, N. P., Padmanabhan, L., & Mora, S. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000675 · Cited by 74
Calabresi, L., Simonelli, S., Conca, P., Busnach, G., Cabibbe, M., Gesualdo, L., Gigante, M., Penco, S., Veglia, F., & Franceschini, G. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12290 · Cited by 71
Grover, S. A., Kaouache, M., Joseph, L., Barter, P., & Davignon, J. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.328 · Cited by 69
Self-citationMichos, E. D., Sibley, C. T., Baer, J., Blaha, M. J., & Blumenthal, R. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.045 · Cited by 68
The correlation between serum lipid profile with carotid intima-media thickness and plaque
Yang, C., Sun, Z., Li, Y., Ai, J., Sun, Q., & Tian, Y. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-181 · Cited by 79
Bochem, A. E., van Wijk, D. F., Holleboom, A. G., Duivenvoorden, R., Motazacker, M. M., Dallinga-Thie, G. M., de Groot, E., Kastelein, J. J. P., Nederveen, A. J., Hovingh, G. K., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs376 · Cited by 67
Self-citationHDL abnormalities in familial hypercholesterolemia: Focus on biological functions
Ganjali, S., Momtazi‐Borojeni, A. A., Banach, M., Kovanen, P. T., Stein, E. A., & Sahebkar, A. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.05.001 · Cited by 72
Miyamoto–Sasaki, M., Yasuda, T., Monguchi, T., Nakajima, H., Mori, K., Toh, R., Ishida, T., & Hirata, K. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.17210 · Cited by 67
Should low high-density lipoprotein cholesterol (HDL-C) be treated?
Toth, P. P., Barylski, M., Nikolić, D., Rizzo, M., Montalto, G., & Banach, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.11.002 · Cited by 73
High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders
Linthout, S. V., Spillmann, F., Schultheiss, H., & Tschöpe, C. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791051031 · Cited by 77
The Therapeutic Role of Niacin in Dyslipidemia Management
Boden, W. E., Sidhu, M. S., & Toth, P. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413514481 · Cited by 74
Chai, S. C., Davis, K., Wright, R. S., Kuczmarski, M. F., & Zhang, Z. (2018) · Food & Function · doi:10.1039/c8fo00468d · Cited by 75
HDL-Cholesterol, Its Variability, and the Risk of Diabetes: A Nationwide Population-Based Study
Lee, S., Kim, H., Park, Y., Kwon, H., Yoon, K., Han, K., & Kim, M. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01080 · Cited by 72
Physical Activity and Lipid Profile in the ELSA-Brasil Study
da Silva, R. C., Diniz, M. D. F. H. S., Alvim, S., Vidigal, P. G., Fedeli, L., & Barreto, S. M. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160091 · Cited by 125
HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels
Annema, W., Willemsen, H. M., de Boer, J. F., Dikkers, A., van der Giet, M., Nieuwland, W., Kobold, A. C. M., van Pelt, L. J., Slart, R. H. J. A., van der Horst, I. C. C., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.003 · Cited by 75
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Increased Pancreatic Fat Fraction Is Present in Obese Adolescents With Metabolic Syndrome
Maggio, A. B. R., Mueller, P., Wacker, J., Viallon, M., Belli, D. C., Beghetti, M., Farpour‐Lambert, N. J., & McLin, V. A. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318244a685 · Cited by 69
How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 69
HDL cholesterol and ASCVD risk stratification: A debate
Barter, P. J., & Genest, J. J. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.001 · Cited by 72
Self-citationABCA1, ABCG1, and Cholesterol Homeostasis
Yu, X.-H., & Tang, C. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_7 · Cited by 79
Konishi, H., Miyauchi, K., Kasai, T., Tsuboi, S., Ogita, M., Naito, R., Sai, E., Fukushima, Y., Katoh, Y., Okai, I., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.015 · Cited by 71
Yin, K., Deng, X., Mo, Z.-C., Zhao, G.-J., Jiang, J., Cui, L.-B., Tan, C.-Z., Wen, G.-B., Fu, Y., & Tang, C.-K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202275 · Cited by 64
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Farnier, M. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3390 · Cited by 63
Colin, S., Briand, O., Touche, V., Wouters, K., Baron, M., Pattou, F., Hanf, R., Tailleux, A., Chinetti, G., Staels, B., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs227 · Cited by 63
HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
Bhatt, A. B., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0554-1 · Cited by 73
Tang, C., Houston, B. A., Storey, C., & LeBoeuf, R. C. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m065797 · Cited by 65
Hypercholesterolemia Induces Oxidant Stress That Accelerates the Ageing of Hematopoietic Stem Cells
Tie, G., Messina, K. E., Yan, J., Messina, J. A., & Messina, L. M. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000241 · Cited by 62
Teramoto, T., Shimano, H., Yokote, K., & Urashima, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1719 · Cited by 62
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk
Allard‐Ratick, M., Kindya, B., Khambhati, J., Engels, M. C., Sandesara, P. B., Rosenson, R. S., & Sperling, L. S. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319848214 · Cited by 67
Couffinhal, T., Savel, Lafitte, Couffinhal, T., & Tabarin (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s29985 · Cited by 63
“Introduction Several studies have demonstrated an inverse correlation between plasma high-density lipoprotein (HDL) and the risk of coronary artery disease, and have concluded that HDL is a powerful predictor of the disease.(1,2) Mutations in lecithin-cholesterol acyltransferase (LCAT), apolipoprotein A-1 (ApoA-1), an…”
Kingwell, B. A., & Chapman, M. J. (2013) · Circulation · doi:10.1161/circulationaha.113.002683 · Cited by 68
Nakanishi, S., Vikstedt, R., Söderlund, S., Lee-Rueckert, M., Hiukka, A., Ehnholm, C., Muilu, M., Metso, J., Naukkarinen, J., Palotie, L., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800196-jlr200 · Cited by 60
Dong, S., Zhang, K., Guo, Y., Ding, J., Feng, J.-C., Yao, S., Yao, S., Rong, Y., Jiang, F., Chen, J., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00865-3 · Cited by 72
Chirovsky, D. R., Fedirko, V., Cui, Y. A., Sazonov, V., & Barter, P. J. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32832c8891 · Cited by 63
Self-citationSpotlight on HDL-raising therapies: insights from the torcetrapib trials
Kontush, A., Guérin, M., & Chapman, M. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1191 · Cited by 67
Tietjen, I., Hovingh, G. K., Singaraja, R., Radomski, C., McEwen, J., Chan, E., Mattice, M., Legendre, A., Kastelein, J. J. P., & Hayden, M. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.08.006 · Cited by 58
Self-citationBallantyne, C. M., Miller, M. J., Niesor, E. J., Burgess, T., Kallend, D. G., & Stein, E. A. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.017 · Cited by 59
Bekx, M. T., Connor, E. L., & Allen, D. B. (2009) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2009.04.004 · Cited by 65
Cui, Y. A., Watson, D. J., Girman, C. J., Shapiro, D. R., Gotto, A. M., Hiserote, P., & Clearfield, M. B. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.020 · Cited by 57
Self-citationHigh‐density lipoprotein exerts vasculoprotection via endothelial progenitor cells
Petoumenos, V., Nickenig, G., & Werner, N. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00472.x · Cited by 67
Pan, B., Ren, H., He, Y., Lv, X., Ma, Y., Li, J., Huang, L. T., Yu, B., Kong, J., Niu, C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0817 · Cited by 56
“6 High-density lipoprotein (HDL) contributes importantly to cardiovascular disease risk, with a significant inverse relationship between HDL levels and the risk of cardiovascular disease (17-20).”
BackgroundBesler, C., Heinrich, K., Riwanto, M., Lüscher, T. F., & Landmesser, U. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791051013 · Cited by 58
Metabolism Regulation and Redox State: Insight into the Role of Superoxide Dismutase 1
Damiano, S., Sozio, C., Rosa, G. L., Guida, B., Faraonio, R., Santillo, M., & Mondola, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186606 · Cited by 60
Role of HDL in Those with Diabetes
Santos‐Gallego, C. G., & Rosenson, R. S. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0512-5 · Cited by 65
Eyeballing cholesterol efflux and macrophage function in disease pathogenesis
Sene, A., & Apte, R. S. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.007 · Cited by 56
Combination therapy of statins and fibrates in the management of cardiovascular risk
Fiévet, C., & Staels, B. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328332e9ef · Cited by 60
Biological potential and technological applications of red fruits: An overview
Bortolini, D. G., Maciel, G. M., Fernandes, I. D. A. A., Rossetto, R., Brugnari, T., Ribeiro, V. R., & Haminiuk, C. W. I. (2022) · Food Chemistry Advances · doi:10.1016/j.focha.2022.100014 · Cited by 59
Bai, Q., Zhang, X., Xu, L., Kakiyama, G., Heuman, D. M., Sanyal, A. J., Pandak, W. M., Yin, L., Xie, W., & Ren, S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.11.014 · Cited by 58
“It has been shown that the patients with high VLDL and LDL and low HDL are at a higher risk of myocardial infarction and sudden death [29-32].”
Danielsen, Y. S., Nordhus, I. H., Júlíusson, P. B., Mæhle, M. O., & Pallesen, S. (2012) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2012.06.003 · Cited by 65
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders
Scheen, A. J., & Paquot, N. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.001 · Cited by 59
Seo, S. M., Choo, E. H., Koh, Y. S., Park, M., Shin, D.-I., Choi, Y. S., PARK, H., Kim, D. B., Her, S., Lee, J. M., et al. (2011) · Heart · doi:10.1136/hrt.2011.225466 · Cited by 58
Liang, Y., Yan, Z., Sun, B., Cai, C., Jiang, H., Song, A., & Qiu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085927 · Cited by 55
Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes
Abdel-Maksoud, M. F., Sazonov, V., Gutkin, S. W., & Hokanson, J. E. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318165e2e7 · Cited by 57
Pathophysiology of diabetic dyslipidemia:implications for atherogenesis and treatment
Sugden, M., & Holness, M. (2011) · Clinical Lipidology · doi:10.2217/clp.11.32 · Cited by 62
Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.01.01 · Cited by 53
Self-citationAn Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 57
Arai, H., Hiro, T., Kimura, T., Morimoto, T., Miyauchi, K., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Kimura, K., Saito, S., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5660 · Cited by 53
Touboul, P., Labreuche, J., Bruckert, É., Schargrodsky, H., Prati, P., Tosetto, A., Hernández-Hernández, R., Woo, K.-S., Silva, H., Vicaut, É., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.10.011 · Cited by 61
Bornhoeft, J., Castaneda, D., Nemoseck, T., Wang, P., Henning, S. M., & Hong, M. Y. (2012) · Journal of Medicinal Food · doi:10.1089/jmf.2011.0258 · Cited by 59
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Saitō, Y. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5551 · Cited by 56
Atherogenesis and atherothrombosis – focus on diabetes mellitus
Stratmann, B., & Tschoepe, D. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.12.004 · Cited by 59
Chiefari, E., Tanyolaç, S., Iiritano, S., Sciacqua, A., Capula, C., Arcidiacono, B., Nocera, A., Possidente, K., Baudi, F., Ventura, V., et al. (2013) · Scientific Reports · doi:10.1038/srep01491 · Cited by 52
Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments
Digby, J. E., Ruparelia, N., & Choudhury, R. P. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.236315 · Cited by 53
Gatti, A., Maranghi, M., Bacci, S., Carallo, C., Gnasso, A., Mandosi, E., Fallarino, M., Morano, S., Trischitta, V., & Filetti, S. (2009) · Diabetes Care · doi:10.2337/dc09-0256 · Cited by 57
Berge, R. K., Ramsvik, M. S., Bohov, P., Svardal, A., Nordrehaug, J. E., Rostrup, E., Bruheim, I., & Bjørndal, B. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0162-7 · Cited by 51
González‐Pacheco, H., Vallejo, M., Altamirano‐Castillo, A., Vargas‐Barrón, J., Piña-Reyna, Y., Sánchez-Tapia, P., & Martínez‐Sánchez, C. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s67945 · Cited by 75
Yeh, P.-S., Yang, C.-M., Lin, S., Wang, W.-M., Chen, P.-S., Chao, T., Lin, H.-J., Lin, K., Chang, C., Cheng, T., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.03.015 · Cited by 57
Lipoprotein-specific transport of circulating lipid peroxides
Ahotupa, M., Suomela, J.-P., Vuorimaa, T., & Vasankari, T. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.510932 · Cited by 51
Association Between Serum Cholesterol and Noncardiovascular Mortality in Older Age
Newson, R. S., Felix, J. F., Heeringa, J., Hofman, A., Witteman, J. C. M., & Tiemeier, H. W. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03593.x · Cited by 53
Pitavastatin – pharmacological profile from early phase studies
Catapano, A. L. (2010) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(10)71063-1 · Cited by 58
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.